Collaborative Arrangements (Tables)

9 Months Ended

Sep. 30, 2016

Collaborative Arrangements

Schedule of revenue recognized from collaborative arrangements

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2016		2015		2016		2015
Mylan	$	25	$	25	$	15,076	$	19,149
Takeda Pharmaceuticals	15,075		—		15,075		—
SciClone Pharmaceuticals	2		2		6		2,952
R-Pharm	9		9		35		2,040
Trek Therapeutics	—		8,000		—		8,000
Other	63		350		193		376
Total revenue from collaborative arrangements	$	15,174	$	8,386	$	30,385	$	32,517

Summary of reductions to R&D costs related to the reimbursement payments

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2016		2015		2016		2015
Mylan	$	18,638	$	10,128	$	75,782	$	25,869
Alfa Wassermann	2,607		704		6,393		1,493
SciClone	—		—		98		—
R-Pharm	17		130		42		407
Total reduction to R&D expense	$	21,262	$	10,962	$	82,315	$	27,769